SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways

Cellular Physiology and Biochemistry

Volumn 35, Issue 3, 2015, Pages 1116-1124

  Ruan, Yang ^a   Dong, Chunlin ^a   Patel, Jigar ^b   Duan, Chao ^c   Wang, Xinyue ^d   Wu, Xi ^d   Cao, Yuan ^d   Pu, Lianmei ^a   Lu, Dan ^a   Shen, Tao ^d   Li, Jian ^d  

^a The First People's Hospital of Jinzhou District   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BEIJING TECHNOLOGY AND BUSINESS UNIVERSITY   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

Apoptosis; Cardiomyocyte; Doxorubicin; Oxidative stress; p38MAPK; Sirtuin 1

Indexed keywords

CASPASE 3; COPPER ZINC SUPEROXIDE DISMUTASE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; SIRT1 PROTEIN, RAT; STILBENE DERIVATIVE;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DAMAGE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE MODEL; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ADENOVIRIDAE; RATTUS;

ANIMALS; APOPTOSIS; CELL LINE; DOXORUBICIN; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; MICE; MYOCYTES, CARDIAC; NIACINAMIDE; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES;

EID: 84924661271     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373937     Document Type: Article

References (23)

1. van Dalen EC, van den BM, Caron HN, Kremer LC: Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer 2006;42:3199-3205.
2. Dent P: The flip side of doxorubicin: Inflammatory and tumor promoting cytokines. Cancer Biol Ther 2013;14:774-775.
3. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS: Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:3159-3165.
4. Longhi A, Ferrari S, Bacci G, Specchia S: Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 2007;18:737-744.
5. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, Foley B, Bourge RC: Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005;24:2196-2201.
6. Kara G, Tasoglu O, Dizdar O, Altundag K, Ozcakar L: Stroke due to doxorubicin-induced cardiac toxicity. Med Oncol 2009;26:506-507.
7. Lin ST, Chou HC, Chen YW, Chan HL: Redox-proteomic analysis of doxorubicin-induced altered thiol activity in cardiomyocytes. Mol Biosyst 2013;9:447-456.
8. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-1642.
9. Chang HC, Guarente L: SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 2014;25:138-145.
10. Hubbard BP, Sinclair DA: Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014;35:146-154.
11. Palomer X, varez-Guardia D, Rodriguez-Calvo R, Coll T, Laguna JC, Davidson MM, Chan TO, Feldman AM, Vazquez-Carrera M: TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc Res 2009;81:703-712.
12. Martin ED, Bassi R, Marber MS: p38 MAPK in cardioprotection-are we there yet? Br J Pharmacol 2014.
13. Cao Y, Ruan Y, Shen T, Huang X, Li M, Yu W, Zhu Y, Man Y, Wang S, Li J: Astragalus Polysaccharide Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the PI3k/Akt and p38MAPK Pathways. Oxid Med Cell Longev 2014;2014:674219.
14. Shen T, Yang C, Ding L, Zhu Y, Ruan Y, Cheng H, Qin W, Huang X, Zhang H, Man Y, Liu D, Wang S, Bian Y, Xiao C, Zhao Y, Li J: Tbx20 functions as an important regulator of estrogen-mediated cardiomyocyte protection during oxidative stress. Int J Cardiol 2013;168:3704-3714.
15. Shen T, Aneas I, Sakabe N, Dirschinger RJ, Wang G, Smemo S, Westlund JM, Cheng H, Dalton N, Gu Y, Boogerd CJ, Cai CL, Peterson K, Chen J, Nobrega MA, Evans SM: Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function. J Clin Invest 2011;121:4640-4654.
16. Fatima N, Zaman MU, Hashmi A, Kamal S, Hameed A: Assessing adriamycin-induced early cardiotoxicity by estimating left ventricular ejection fraction using technetium-99m multiple-gated acquisition scan and echocardiography. Nucl Med Commun 2011;32:381-385.
17. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048-1056.
18. Nabeebaccus A, Zhang M, Shah AM: NADPH oxidases and cardiac remodelling. Heart Fail Rev 2011;16:5-12.
19. Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N, Banba K, Nagase S, Miyaji K, Morita H, Saito H, Emori T, Ohe T: Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 2005;11:117-123.
20. Yeh CC, Li H, Malhotra D, Turcato S, Nicholas S, Tu R, Zhu BQ, Cha J, Swigart PM, Myagmar BE, Baker AJ, Simpson PC, Mann MJ: Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J Cell Biochem 2010;109:1185-1191.
21. Consoli C, Gatta L, Iellamo F, Molinari F, Rosano GM, Marlier LN: Severity of left ventricular dysfunction in heart failure patients affects the degree of serum-induced cardiomyocyte apoptosis. Importance of inflammatory response and metabolism. Int J Cardiol 2013;167:2859-2866.
22. Poulsen MM, Jorgensen JO, Jessen N, Richelsen B, Pedersen SB: Resveratrol in metabolic health: an overview of the current evidence and perspectives. Ann N Y Acad Sci 2013;1290:74-82.
23. Marchal J, Pifferi F, Aujard F: Resveratrol in mammals: effects on aging biomarkers, age-related diseases, and life span. Ann N Y Acad Sci 2013;1290:67-73.